Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Dec;81(8):1344–1350. doi: 10.1038/sj.bjc.6693248

Pleuro-pulmonary tumours detected by clinical and chest X-ray analyses in rats transplanted with mesothelioma cells

F Le Pimpec-Barthes 1, I Bernard 2, I Abd Alsamad 4, A Renier 5, L Kheuang 5, J Fleury-Feith 6, P Devauchelle 3, F Quintin Colonna 2, M Riquet 1, M C Jaurand 5
PMCID: PMC2362982  PMID: 10604731

Abstract

New strategies for cancer therapy must be developed, especially in severe neoplasms such as malignant pleural mesothelioma. Animal models of cancer, as close as possible to the human situation, are needed to investigate novel therapeutical approaches. Orthotopic transplantation of cancer cells is then relevant and efforts should be made to follow up tumour evolution in animals. In the present study, we developed a method for the orthotopic growth of mesothelioma cells in the pleural cavity of Fischer 344 and nude rats, along with a procedure for clinical survey. Two mesothelioma cell lines, of rat and human origin, were inoculated by transthoracic puncture. Body weight determination and chest X-ray analyses permitted the follow-up of tumour evolution by identifying different stages. Autopsies showed that tumours localized on the whole pleural cavity (diaphragm, parietal pleura), mediastinum and pericardium. Tumour morphology and antigenic characteristics were consistent with those of the inoculated cells and were similar in both types of rats inoculated with the same cell type. These results demonstrate that mesothelioma formation in rats can be followed up by clinical and radiographic survey after gentle intrathoracic inoculation of mesothelioma cells, thus allowing the definition of stages of interest for further experimental trials. © 1999 Cancer Research Campaign

Keywords: culture, malignant mesothelioma, nude rats, transplantation

Full Text

The Full Text of this article is available as a PDF (857.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Astoul P., Viallat J. R., Laurent J. C., Brandely M., Boutin C. Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion. Chest. 1993 Jan;103(1):209–213. doi: 10.1378/chest.103.1.209. [DOI] [PubMed] [Google Scholar]
  2. Baselga J., Mendelsohn J. The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res Treat. 1994 Jan;29(1):127–138. doi: 10.1007/BF00666188. [DOI] [PubMed] [Google Scholar]
  3. Bishop J. F. Scheduling of chemotherapy and radiotherapy in locally advanced non-small cell lung cancer. Lung Cancer. 1995 Jun;12 (Suppl 2):S53–S61. doi: 10.1016/s0169-5002(10)80006-6. [DOI] [PubMed] [Google Scholar]
  4. Carbone M., Rizzo P., Pass H. I. Simian virus 40, poliovaccines and human tumors: a review of recent developments. Oncogene. 1997 Oct 16;15(16):1877–1888. doi: 10.1038/sj.onc.1201375. [DOI] [PubMed] [Google Scholar]
  5. Chahinian A. P., Kirschner P. A., Gordon R. E., Szrajer L., Holland J. F. Usefulness of the nude mouse model in mesothelioma based on a direct patient-xenograft comparison. Cancer. 1991 Aug 1;68(3):558–560. doi: 10.1002/1097-0142(19910801)68:3<558::aid-cncr2820680319>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  6. Davis B. M., Koc O. N., Lee K., Gerson S. L. Current progress in the gene therapy of cancer. Curr Opin Oncol. 1996 Nov;8(6):499–508. doi: 10.1097/00001622-199611000-00010. [DOI] [PubMed] [Google Scholar]
  7. Esandi M. C., van Someren G. D., Vincent A. J., van Bekkum D. W., Valerio D., Bout A., Noteboom J. L. Gene therapy of experimental malignant mesothelioma using adenovirus vectors encoding the HSVtk gene. Gene Ther. 1997 Apr;4(4):280–287. doi: 10.1038/sj.gt.3300385. [DOI] [PubMed] [Google Scholar]
  8. Fleury-Feith J., Nebut M., Saint-Etienne L., Laurent P., Pinchon M. C., Kheuang L., Renier A., Jaurand M. C. Occurrence and morphology of tumors induced in nude mice transplanted with chrysotile-transformed rat pleural mesothelial cells. Biol Cell. 1989;65(1):45–50. [PubMed] [Google Scholar]
  9. Gutman M., Fidler I. J. Biology of human colon cancer metastasis. World J Surg. 1995 Mar-Apr;19(2):226–234. doi: 10.1007/BF00308631. [DOI] [PubMed] [Google Scholar]
  10. Hoogsteden H. C., Langerak A. W., van der Kwast T. H., Versnel M. A., van Gelder T. Malignant pleural mesothelioma. Crit Rev Oncol Hematol. 1997 Feb;25(2):97–126. doi: 10.1016/s1040-8428(96)00231-4. [DOI] [PubMed] [Google Scholar]
  11. Hwang H. C., Smythe W. R., Elshami A. A., Kucharczuk J. C., Amin K. M., Williams J. P., Litzky L. A., Kaiser L. R., Albelda S. M. Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am J Respir Cell Mol Biol. 1995 Jul;13(1):7–16. doi: 10.1165/ajrcmb.13.1.7598939. [DOI] [PubMed] [Google Scholar]
  12. Jaurand M. C., Fleury J., Monchaux G., Nebut M., Bignon J. Pleural carcinogenic potency of mineral fibers (asbestos, attapulgite) and their cytotoxicity on cultured cells. J Natl Cancer Inst. 1987 Oct;79(4):797–804. [PubMed] [Google Scholar]
  13. Monchaux G., Bignon J., Jaurand M. C., Lafuma J., Sebastien P., Masse R., Hirsch A., Goni J. Mesotheliomas in rats following inoculation with acid-leached chrysotile asbestos and other mineral fibres. Carcinogenesis. 1981;2(3):229–236. doi: 10.1093/carcin/2.3.229. [DOI] [PubMed] [Google Scholar]
  14. Perrin D., Halazy S., Hill B. Inhibiteurs de farnésylation de Ras: agents anticancéreux de demain? Bull Cancer. 1997 Jun;84(6):635–642. [PubMed] [Google Scholar]
  15. Ross G., Erickson R., Knorr D., Motulsky A. G., Parkman R., Samulski J., Straus S. E., Smith B. R. Gene therapy in the United States: a five-year status report. Hum Gene Ther. 1996 Sep 10;7(14):1781–1790. doi: 10.1089/hum.1996.7.14-1781. [DOI] [PubMed] [Google Scholar]
  16. Smythe W. R., Kaiser L. R., Hwang H. C., Amin K. M., Pilewski J. M., Eck S. J., Wilson J. M., Albelda S. M. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann Thorac Surg. 1994 Jun;57(6):1395–1401. doi: 10.1016/0003-4975(94)90090-6. [DOI] [PubMed] [Google Scholar]
  17. Sterman D. H., Treat J., Litzky L. A., Amin K. M., Coonrod L., Molnar-Kimber K., Recio A., Knox L., Wilson J. M., Albelda S. M. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther. 1998 May 1;9(7):1083–1092. doi: 10.1089/hum.1998.9.7-1083. [DOI] [PubMed] [Google Scholar]
  18. Togo S., Shimada H., Kubota T., Moossa A. R., Hoffman R. M. Host organ specifically determines cancer progression. Cancer Res. 1995 Feb 1;55(3):681–684. [PubMed] [Google Scholar]
  19. Zeng L., Fleury-Feith J., Monnet I., Boutin C., Bignon J., Jaurand M. C. Immunocytochemical characterization of cell lines from human malignant mesothelioma: characterization of human mesothelioma cell lines by immunocytochemistry with a panel of monoclonal antibodies. Hum Pathol. 1994 Mar;25(3):227–234. doi: 10.1016/0046-8177(94)90192-9. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES